已入深夜,您辛苦了!由于当前在线用户较少,发布求助请尽量完整的填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!祝你早点完成任务,早点休息,好梦!

Adjustable intragastric balloon for treatment of obesity: a multicentre, open-label, randomised clinical trial.

医学 减肥 耐受性 临床试验 随机对照试验 人口 肥胖 内科学 气球 外科 不利影响
作者
Barham K Abu Dayyeh,Daniel B Maselli,Babusai Rapaka,Thomas Lavin,Mark Noar,Hisham Hussan,Christopher G Chapman,Violeta Popov,Pichamol Jirapinyo,Andres Acosta,Eric J Vargas,Andrew C Storm,Fateh Bazerbachi,Marvin Ryou,Matthew French,Sabrena Noria,Daniel Molina,Christopher C Thompson
出处
期刊:The Lancet [Elsevier]
卷期号:398 (10315): 1965-1973 被引量:7
标识
DOI:10.1016/s0140-6736(21)02394-1
摘要

Intragastric balloons are anatomy-preserving, minimally invasive obesity therapies. Enhanced tolerance and durability could help broaden clinical adoption. We investigated the safety and efficacy of an adjustable intragastric balloon (aIGB) in adults with obesity.In this prospective, multicentre, open-label, randomised clinical trial done at seven US sites, adults aged 22-65 years with obesity were randomly assigned (2:1) to aIGB with lifestyle intervention or lifestyle intervention alone (control) for 32 weeks. Balloon volume could be increased to facilitate weight loss or decreased for tolerability. Coprimary endpoints included mean percentage total bodyweight loss and responder rate (≥5% total bodyweight loss) at 32 weeks. We used a multiple imputed intention-to-treat population analysis. This study was registered with ClinicalTrials.gov, NCT02812160.Between Aug 9, 2016, and Dec 7, 2018, we randomly assigned 288 patients to aIGB (n=187 [65%]) or control (n=101 [35%]) groups. Mean total bodyweight loss at 32 weeks was 15·0% (95% CI 13·9-16·1) in the aIGB group versus 3·3% (2·0-4·6) in the control group (p<0·0001). Clinical response was observed in 171 (92%) patients in the aIGB group. Adjustments to the aIGB occurred in 145 (80%) patients for weight loss plateau or intolerance. Upward volume adjustment facilitated an additional mean 5·2% (4·5-5·8) total bodyweight loss. Downward volume adjustment allowed 21 (75%) patients in the aIGB group to complete the full duration of therapy. Intolerance caused early removal of the device in 31 (17%) patients. No micronutrient deficiencies were observed in the aIGB cohort. Device-related serious adverse events were observed in seven (4%) patients, without any deaths.When aIGB was combined with lifestyle modification, significant weight loss was achieved and maintained for 6 months following removal. Balloon volume adjustability permitted individualised therapy, maximising weight loss and tolerance.Spatz Medical.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
良景似尘完成签到 ,获得积分10
1秒前
君知完成签到,获得积分10
2秒前
Rsquo完成签到,获得积分10
6秒前
6秒前
7秒前
ShiYanYang完成签到,获得积分10
9秒前
CodeCraft应助科研达人采纳,获得30
10秒前
vio_107发布了新的文献求助10
11秒前
明亮翠桃发布了新的文献求助10
11秒前
可爱的函函应助ZHH采纳,获得10
13秒前
英俊的铭应助唐擎汉采纳,获得10
14秒前
15秒前
热情醉山完成签到,获得积分20
15秒前
Masche发布了新的文献求助50
18秒前
王特工发布了新的文献求助10
19秒前
吡咯爱成环应助Yuantian采纳,获得20
23秒前
24秒前
24秒前
科目三应助神经蛙采纳,获得10
27秒前
Ghiocel发布了新的文献求助30
29秒前
pear发布了新的文献求助10
29秒前
29秒前
灵巧寄风发布了新的文献求助10
30秒前
30秒前
30秒前
34秒前
35秒前
Vroom发布了新的文献求助20
36秒前
yaney完成签到,获得积分10
36秒前
37秒前
37秒前
许中原发布了新的文献求助10
38秒前
雪霓裳完成签到 ,获得积分10
38秒前
Henry应助恰同学少年采纳,获得200
41秒前
Ling发布了新的文献求助10
41秒前
零下一秒发布了新的文献求助10
41秒前
思源应助科研通管家采纳,获得10
42秒前
42秒前
42秒前
搜集达人应助科研通管家采纳,获得10
42秒前
高分求助中
Production Logging: Theoretical and Interpretive Elements 2500
Healthcare Finance: Modern Financial Analysis for Accelerating Biomedical Innovation 2000
Applications of Emerging Nanomaterials and Nanotechnology 1111
Agaricales of New Zealand 1: Pluteaceae - Entolomataceae 1040
Les Mantodea de Guyane Insecta, Polyneoptera 1000
Neuromuscular and Electrodiagnostic Medicine Board Review 700
지식생태학: 생태학, 죽은 지식을 깨우다 600
热门求助领域 (近24小时)
化学 医学 材料科学 生物 工程类 有机化学 生物化学 纳米技术 内科学 物理 化学工程 计算机科学 复合材料 基因 遗传学 物理化学 催化作用 细胞生物学 免疫学 电极
热门帖子
关注 科研通微信公众号,转发送积分 3466610
求助须知:如何正确求助?哪些是违规求助? 3059468
关于积分的说明 9066340
捐赠科研通 2749950
什么是DOI,文献DOI怎么找? 1508779
科研通“疑难数据库(出版商)”最低求助积分说明 697059
邀请新用户注册赠送积分活动 696883